You’ve been lied to about American wealth. Not by the left, not by the right—but by everyone who tells you it’s all just inequality. The data is clear: Americans are richer than everyone else. But the reason isn’t what you think.
Every time you see a chart comparing the US to Europe, two narratives fight for your attention. One says: ‘See? America works. Our GDP per capita crushes everyone else.’ The other says: ‘But look at the median. Look at the healthcare. Look at the inequality. It’s all a mirage.’ Both are right—and both are dangerously incomplete.
I spent weeks digging into the numbers behind the famous Cremieux analysis. What I found made me rethink everything I thought I knew about comparative economics. The American wealth advantage isn’t a trick of inequality—it’s a product of sheer output per worker. The average American produces more value per hour than any other major economy. That’s not a bug—it’s the feature everyone ignores.
But here’s where it gets uncomfortable. That productivity advantage is fueled by something most people hate: the American healthcare system. Yes, the same system that bankrupts families and leaves millions uninsured. America’s healthcare system is a terrible way to deliver health, but a brilliant way to fund innovation. The US spends more on healthcare than any other country, and that overspending isn’t just waste—it’s a global subsidy for pharmaceutical R&D, medical device patents, and biotech breakthroughs. Every cancer drug, every new surgical technique, every AI diagnostic tool that the world uses—it was largely paid for by American patients and taxpayers.
This is the brutal trade-off that nobody wants to talk about. If you cut US healthcare spending to European levels without replacing that innovation engine, the wealth advantage shrinks. The productivity gap narrows. The US becomes more like Europe—not just in healthcare, but in overall economic output. You can’t fix the healthcare system without understanding that it’s also the goose that lays the golden eggs.
I asked an economist who studies this: ‘What would happen if we just adopted Medicare for All tomorrow?’ He laughed. ‘We’d save money on healthcare, but we’d lose the innovation premium. The US would still be rich, but not as rich. And the rest of the world would lose the pipeline of new treatments.’
This isn’t an argument for the status quo. It’s an argument for seeing the full picture. The real fight isn’t about inequality—it’s about whether you want to kill the goose that lays the golden eggs.
So next time you hear someone say ‘America’s wealth is just inequality,’ ask them why the productivity advantage exists. The answer might make you rethink everything.
FAQ
Q: Isn't US healthcare spending just wasteful? How can it be an engine of wealth?
A: The US spends roughly 17% of GDP on healthcare, far more than any other country. Much of that is administrative waste and high prices. But the high prices also fund massive R&D investment—pharmaceutical companies, medical device makers, and biotech firms concentrate their innovation in the US because they can charge higher prices here. That innovation then flows to the rest of the world. So while the delivery system is inefficient, the funding mechanism has a hidden benefit: it makes the US the global leader in medical innovation.
Q: So should we stop trying to fix healthcare?
A: No. The argument is not that the status quo is optimal. It's that any reform must account for the innovation engine. Simply cutting prices and spending without investing in an alternative R&D system could reduce American productivity and wealth over time. The ideal solution would be to decouple healthcare delivery from innovation funding—for example, by having the government directly fund R&D while using price controls for delivery. But that's politically difficult.
Q: What if the European model is actually better for long-term well-being?
A: That's a values question, not an economic one. If you prioritize life expectancy, lower infant mortality, and financial security from medical bills, the European model wins. But you also accept lower GDP per capita, slower innovation, and less access to cutting-edge treatments. The US model trades higher average wealth and faster innovation for worse health outcomes and higher inequality. There's no 'right' answer—only trade-offs.